The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Diabetic Therapeutic Market Research Report 2025

Global Diabetic Therapeutic Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1713587

No of Pages : 110

Ask Your Query

Synopsis

Market Analysis and Insights: Global Diabetic Therapeutic Market

The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.

The global Diabetic Therapeutic market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

The report identifies the increasing focus on the self-management of diabetes to be one of the major factors that will have a positive impact on the growth of this market in the coming years. With the recent years witnessing an increase in number of people diagnosed with type 1 diabetes, there has been considerable increase in the adoption of insulin delivery systems. Focusing on skipping the need to schedule appointments and reduce expenses for clinical visits, increases the adoption of insulin delivery systems, where individuals use insulin injections at home under the guidance of a physician. This led to the introduction of insulin pens, pumps, and jet injectors, which, in turn, will drive the growth of the diabetic therapeutics market.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Therapeutic market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Therapeutic market.

Global Diabetic Therapeutic Scope and Market Size
Diabetic Therapeutic market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Diabetic Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Sulphonylureas
  • Biguanides
  • Meglitinides
  • Thiazolidinediones
  • Alpha-glucosidase Inhibitors
  • DPP-4 Inhibitors
  • SGLT-2 Inhibitors

Segment by Application

  • Diagnostic/Clinics
  • ICUs
  • Home Healthcare

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

By Company

  • Sanofi
  • Novo Nordisk
  • Msd
  • Astrazeneca
  • Takeda
  • Novartis
  • Abbvie
  • Eli Lilly
  • North China Pharmaceutical Group Corporation
  • Huadong Medicine
  • Dongbao Pharmaceutical
  • Hisun Pharmacy
  • Kelun
  • Ginwa
  • Tianan Pharmaceutical
  • Jumpcan Pharmacy
  • Guangzhou Baiyun Mountain
  • Shijiazhuang Yiling Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Gan & Lee
  • Taloph
Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Therapeutic Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Sulphonylureas
1.2.3 Biguanides
1.2.4 Meglitinides
1.2.5 Thiazolidinediones
1.2.6 Alpha-glucosidase Inhibitors
1.2.7 DPP-4 Inhibitors
1.2.8 SGLT-2 Inhibitors
1.3 Market by Application
1.3.1 Global Diabetic Therapeutic Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Diagnostic/Clinics
1.3.3 ICUs
1.3.4 Home Healthcare
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Therapeutic Market Perspective (2017-2028)
2.2 Diabetic Therapeutic Growth Trends by Region
2.2.1 Diabetic Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Diabetic Therapeutic Historic Market Size by Region (2017-2022)
2.2.3 Diabetic Therapeutic Forecasted Market Size by Region (2023-2028)
2.3 Diabetic Therapeutic Market Dynamics
2.3.1 Diabetic Therapeutic Industry Trends
2.3.2 Diabetic Therapeutic Market Drivers
2.3.3 Diabetic Therapeutic Market Challenges
2.3.4 Diabetic Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Therapeutic Players by Revenue
3.1.1 Global Top Diabetic Therapeutic Players by Revenue (2017-2022)
3.1.2 Global Diabetic Therapeutic Revenue Market Share by Players (2017-2022)
3.2 Global Diabetic Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Therapeutic Revenue
3.4 Global Diabetic Therapeutic Market Concentration Ratio
3.4.1 Global Diabetic Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Therapeutic Revenue in 2021
3.5 Diabetic Therapeutic Key Players Head office and Area Served
3.6 Key Players Diabetic Therapeutic Product Solution and Service
3.7 Date of Enter into Diabetic Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Therapeutic Breakdown Data by Type
4.1 Global Diabetic Therapeutic Historic Market Size by Type (2017-2022)
4.2 Global Diabetic Therapeutic Forecasted Market Size by Type (2023-2028)
5 Diabetic Therapeutic Breakdown Data by Application
5.1 Global Diabetic Therapeutic Historic Market Size by Application (2017-2022)
5.2 Global Diabetic Therapeutic Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Diabetic Therapeutic Market Size (2017-2028)
6.2 North America Diabetic Therapeutic Market Size by Country (2017-2022)
6.3 North America Diabetic Therapeutic Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Diabetic Therapeutic Market Size (2017-2028)
7.2 Europe Diabetic Therapeutic Market Size by Country (2017-2022)
7.3 Europe Diabetic Therapeutic Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Therapeutic Market Size (2017-2028)
8.2 Asia-Pacific Diabetic Therapeutic Market Size by Country (2017-2022)
8.3 Asia-Pacific Diabetic Therapeutic Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Diabetic Therapeutic Market Size (2017-2028)
9.2 Latin America Diabetic Therapeutic Market Size by Country (2017-2022)
9.3 Latin America Diabetic Therapeutic Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Therapeutic Market Size (2017-2028)
10.2 Middle East & Africa Diabetic Therapeutic Market Size by Country (2017-2022)
10.3 Middle East & Africa Diabetic Therapeutic Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Diabetic Therapeutic Introduction
11.1.4 Sanofi Revenue in Diabetic Therapeutic Business (2017-2022)
11.1.5 Sanofi Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Diabetic Therapeutic Introduction
11.2.4 Novo Nordisk Revenue in Diabetic Therapeutic Business (2017-2022)
11.2.5 Novo Nordisk Recent Development
11.3 MSD
11.3.1 MSD Company Detail
11.3.2 MSD Business Overview
11.3.3 MSD Diabetic Therapeutic Introduction
11.3.4 MSD Revenue in Diabetic Therapeutic Business (2017-2022)
11.3.5 MSD Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Detail
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Diabetic Therapeutic Introduction
11.4.4 Astrazeneca Revenue in Diabetic Therapeutic Business (2017-2022)
11.4.5 Astrazeneca Recent Development
11.5 Takeda
11.5.1 Takeda Company Detail
11.5.2 Takeda Business Overview
11.5.3 Takeda Diabetic Therapeutic Introduction
11.5.4 Takeda Revenue in Diabetic Therapeutic Business (2017-2022)
11.5.5 Takeda Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Diabetic Therapeutic Introduction
11.6.4 Novartis Revenue in Diabetic Therapeutic Business (2017-2022)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Diabetic Therapeutic Introduction
11.7.4 AbbVie Revenue in Diabetic Therapeutic Business (2017-2022)
11.7.5 AbbVie Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Diabetic Therapeutic Introduction
11.8.4 Eli Lilly Revenue in Diabetic Therapeutic Business (2017-2022)
11.8.5 Eli Lilly Recent Development
11.9 North China Pharmaceutical Group Corporation
11.9.1 North China Pharmaceutical Group Corporation Company Detail
11.9.2 North China Pharmaceutical Group Corporation Business Overview
11.9.3 North China Pharmaceutical Group Corporation Diabetic Therapeutic Introduction
11.9.4 North China Pharmaceutical Group Corporation Revenue in Diabetic Therapeutic Business (2017-2022)
11.9.5 North China Pharmaceutical Group Corporation Recent Development
11.10 Huadong Medicine
11.10.1 Huadong Medicine Company Detail
11.10.2 Huadong Medicine Business Overview
11.10.3 Huadong Medicine Diabetic Therapeutic Introduction
11.10.4 Huadong Medicine Revenue in Diabetic Therapeutic Business (2017-2022)
11.10.5 Huadong Medicine Recent Development
11.11 Dongbao Pharmaceutical
11.11.1 Dongbao Pharmaceutical Company Detail
11.11.2 Dongbao Pharmaceutical Business Overview
11.11.3 Dongbao Pharmaceutical Diabetic Therapeutic Introduction
11.11.4 Dongbao Pharmaceutical Revenue in Diabetic Therapeutic Business (2017-2022)
11.11.5 Dongbao Pharmaceutical Recent Development
11.12 Hisun Pharmacy
11.12.1 Hisun Pharmacy Company Detail
11.12.2 Hisun Pharmacy Business Overview
11.12.3 Hisun Pharmacy Diabetic Therapeutic Introduction
11.12.4 Hisun Pharmacy Revenue in Diabetic Therapeutic Business (2017-2022)
11.12.5 Hisun Pharmacy Recent Development
11.13 KELUN
11.13.1 KELUN Company Detail
11.13.2 KELUN Business Overview
11.13.3 KELUN Diabetic Therapeutic Introduction
11.13.4 KELUN Revenue in Diabetic Therapeutic Business (2017-2022)
11.13.5 KELUN Recent Development
11.14 Ginwa
11.14.1 Ginwa Company Detail
11.14.2 Ginwa Business Overview
11.14.3 Ginwa Diabetic Therapeutic Introduction
11.14.4 Ginwa Revenue in Diabetic Therapeutic Business (2017-2022)
11.14.5 Ginwa Recent Development
11.15 Tianan Pharmaceutical
11.15.1 Tianan Pharmaceutical Company Detail
11.15.2 Tianan Pharmaceutical Business Overview
11.15.3 Tianan Pharmaceutical Diabetic Therapeutic Introduction
11.15.4 Tianan Pharmaceutical Revenue in Diabetic Therapeutic Business (2017-2022)
11.15.5 Tianan Pharmaceutical Recent Development
11.16 Jumpcan Pharmacy
11.16.1 Jumpcan Pharmacy Company Detail
11.16.2 Jumpcan Pharmacy Business Overview
11.16.3 Jumpcan Pharmacy Diabetic Therapeutic Introduction
11.16.4 Jumpcan Pharmacy Revenue in Diabetic Therapeutic Business (2017-2022)
11.16.5 Jumpcan Pharmacy Recent Development
11.17 Guangzhou Baiyun Mountain
11.17.1 Guangzhou Baiyun Mountain Company Detail
11.17.2 Guangzhou Baiyun Mountain Business Overview
11.17.3 Guangzhou Baiyun Mountain Diabetic Therapeutic Introduction
11.17.4 Guangzhou Baiyun Mountain Revenue in Diabetic Therapeutic Business (2017-2022)
11.17.5 Guangzhou Baiyun Mountain Recent Development
11.18 SHIJIAZHUANG YILING PHARMACEUTICAL
11.18.1 SHIJIAZHUANG YILING PHARMACEUTICAL Company Detail
11.18.2 SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
11.18.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetic Therapeutic Introduction
11.18.4 SHIJIAZHUANG YILING PHARMACEUTICAL Revenue in Diabetic Therapeutic Business (2017-2022)
11.18.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
11.19 Wanbang Biopharmaceuticals
11.19.1 Wanbang Biopharmaceuticals Company Detail
11.19.2 Wanbang Biopharmaceuticals Business Overview
11.19.3 Wanbang Biopharmaceuticals Diabetic Therapeutic Introduction
11.19.4 Wanbang Biopharmaceuticals Revenue in Diabetic Therapeutic Business (2017-2022)
11.19.5 Wanbang Biopharmaceuticals Recent Development
11.20 Gan & Lee
11.20.1 Gan & Lee Company Detail
11.20.2 Gan & Lee Business Overview
11.20.3 Gan & Lee Diabetic Therapeutic Introduction
11.20.4 Gan & Lee Revenue in Diabetic Therapeutic Business (2017-2022)
11.20.5 Gan & Lee Recent Development
11.21 Taloph
11.21.1 Taloph Company Detail
11.21.2 Taloph Business Overview
11.21.3 Taloph Diabetic Therapeutic Introduction
11.21.4 Taloph Revenue in Diabetic Therapeutic Business (2017-2022)
11.21.5 Taloph Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Diabetic Therapeutic Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Sulphonylureas
Table 3. Key Players of Biguanides
Table 4. Key Players of Meglitinides
Table 5. Key Players of Thiazolidinediones
Table 6. Key Players of Alpha-glucosidase Inhibitors
Table 7. Key Players of DPP-4 Inhibitors
Table 8. Key Players of SGLT-2 Inhibitors
Table 9. Global Diabetic Therapeutic Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Diabetic Therapeutic Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 11. Global Diabetic Therapeutic Market Size by Region (2017-2022) & (US$ Million)
Table 12. Global Diabetic Therapeutic Market Share by Region (2017-2022)
Table 13. Global Diabetic Therapeutic Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 14. Global Diabetic Therapeutic Market Share by Region (2023-2028)
Table 15. Diabetic Therapeutic Market Trends
Table 16. Diabetic Therapeutic Market Drivers
Table 17. Diabetic Therapeutic Market Challenges
Table 18. Diabetic Therapeutic Market Restraints
Table 19. Global Diabetic Therapeutic Revenue by Players (2017-2022) & (US$ Million)
Table 20. Global Diabetic Therapeutic Market Share by Players (2017-2022)
Table 21. Global Top Diabetic Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Therapeutic as of 2021)
Table 22. Ranking of Global Top Diabetic Therapeutic Companies by Revenue (US$ Million) in 2021
Table 23. Global 5 Largest Players Market Share by Diabetic Therapeutic Revenue (CR5 and HHI) & (2017-2022)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Diabetic Therapeutic Product Solution and Service
Table 26. Date of Enter into Diabetic Therapeutic Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Diabetic Therapeutic Market Size by Type (2017-2022) & (US$ Million)
Table 29. Global Diabetic Therapeutic Revenue Market Share by Type (2017-2022)
Table 30. Global Diabetic Therapeutic Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 31. Global Diabetic Therapeutic Revenue Market Share by Type (2023-2028)
Table 32. Global Diabetic Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 33. Global Diabetic Therapeutic Revenue Market Share by Application (2017-2022)
Table 34. Global Diabetic Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 35. Global Diabetic Therapeutic Revenue Market Share by Application (2023-2028)
Table 36. North America Diabetic Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Diabetic Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Diabetic Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 39. Europe Diabetic Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 40. Asia-Pacific Diabetic Therapeutic Market Size by Region (2017-2022) & (US$ Million)
Table 41. Asia-Pacific Diabetic Therapeutic Market Size by Region (2023-2028) & (US$ Million)
Table 42. Latin America Diabetic Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 43. Latin America Diabetic Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 44. Middle East & Africa Diabetic Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 45. Middle East & Africa Diabetic Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 46. Sanofi Company Detail
Table 47. Sanofi Business Overview
Table 48. Sanofi Diabetic Therapeutic Product
Table 49. Sanofi Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 50. Sanofi Recent Development
Table 51. Novo Nordisk Company Detail
Table 52. Novo Nordisk Business Overview
Table 53. Novo Nordisk Diabetic Therapeutic Product
Table 54. Novo Nordisk Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 55. Novo Nordisk Recent Development
Table 56. MSD Company Detail
Table 57. MSD Business Overview
Table 58. MSD Diabetic Therapeutic Product
Table 59. MSD Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 60. MSD Recent Development
Table 61. Astrazeneca Company Detail
Table 62. Astrazeneca Business Overview
Table 63. Astrazeneca Diabetic Therapeutic Product
Table 64. Astrazeneca Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 65. Astrazeneca Recent Development
Table 66. Takeda Company Detail
Table 67. Takeda Business Overview
Table 68. Takeda Diabetic Therapeutic Product
Table 69. Takeda Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 70. Takeda Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Diabetic Therapeutic Product
Table 74. Novartis Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. AbbVie Company Detail
Table 77. AbbVie Business Overview
Table 78. AbbVie Diabetic Therapeutic Product
Table 79. AbbVie Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 80. AbbVie Recent Development
Table 81. Eli Lilly Company Detail
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Diabetic Therapeutic Product
Table 84. Eli Lilly Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. North China Pharmaceutical Group Corporation Company Detail
Table 87. North China Pharmaceutical Group Corporation Business Overview
Table 88. North China Pharmaceutical Group Corporation Diabetic Therapeutic Product
Table 89. North China Pharmaceutical Group Corporation Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 90. North China Pharmaceutical Group Corporation Recent Development
Table 91. Huadong Medicine Company Detail
Table 92. Huadong Medicine Business Overview
Table 93. Huadong Medicine Diabetic Therapeutic Product
Table 94. Huadong Medicine Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 95. Huadong Medicine Recent Development
Table 96. Dongbao Pharmaceutical Company Detail
Table 97. Dongbao Pharmaceutical Business Overview
Table 98. Dongbao Pharmaceutical Diabetic TherapeuticProduct
Table 99. Dongbao Pharmaceutical Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 100. Dongbao Pharmaceutical Recent Development
Table 101. Hisun Pharmacy Company Detail
Table 102. Hisun Pharmacy Business Overview
Table 103. Hisun Pharmacy Diabetic TherapeuticProduct
Table 104. Hisun Pharmacy Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 105. Hisun Pharmacy Recent Development
Table 106. KELUN Company Detail
Table 107. KELUN Business Overview
Table 108. KELUN Diabetic TherapeuticProduct
Table 109. KELUN Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 110. KELUN Recent Development
Table 111. Ginwa Company Detail
Table 112. Ginwa Business Overview
Table 113. Ginwa Diabetic TherapeuticProduct
Table 114. Ginwa Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 115. Ginwa Recent Development
Table 116. Tianan Pharmaceutical Company Detail
Table 117. Tianan Pharmaceutical Business Overview
Table 118. Tianan Pharmaceutical Diabetic TherapeuticProduct
Table 119. Tianan Pharmaceutical Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 120. Tianan Pharmaceutical Recent Development
Table 121. Jumpcan Pharmacy Company Detail
Table 122. Jumpcan Pharmacy Business Overview
Table 123. Jumpcan Pharmacy Diabetic TherapeuticProduct
Table 124. Jumpcan Pharmacy Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 125. Jumpcan Pharmacy Recent Development
Table 126. Guangzhou Baiyun Mountain Company Detail
Table 127. Guangzhou Baiyun Mountain Business Overview
Table 128. Guangzhou Baiyun Mountain Diabetic TherapeuticProduct
Table 129. Guangzhou Baiyun Mountain Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 130. Guangzhou Baiyun Mountain Recent Development
Table 131. SHIJIAZHUANG YILING PHARMACEUTICAL Company Detail
Table 132. SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
Table 133. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetic TherapeuticProduct
Table 134. SHIJIAZHUANG YILING PHARMACEUTICAL Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 135. SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
Table 136. Wanbang Biopharmaceuticals Company Detail
Table 137. Wanbang Biopharmaceuticals Business Overview
Table 138. Wanbang Biopharmaceuticals Diabetic TherapeuticProduct
Table 139. Wanbang Biopharmaceuticals Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 140. Wanbang Biopharmaceuticals Recent Development
Table 141. Gan & Lee Company Detail
Table 142. Gan & Lee Business Overview
Table 143. Gan & Lee Diabetic TherapeuticProduct
Table 144. Gan & Lee Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 145. Gan & Lee Recent Development
Table 146. Taloph Company Detail
Table 147. Taloph Business Overview
Table 148. Taloph Diabetic TherapeuticProduct
Table 149. Taloph Revenue in Diabetic Therapeutic Business (2017-2022) & (US$ Million)
Table 150. Taloph Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Therapeutic Market Share by Type: 2021 VS 2028
Figure 2. Sulphonylureas Features
Figure 3. Biguanides Features
Figure 4. Meglitinides Features
Figure 5. Thiazolidinediones Features
Figure 6. Alpha-glucosidase Inhibitors Features
Figure 7. DPP-4 Inhibitors Features
Figure 8. SGLT-2 Inhibitors Features
Figure 9. Global Diabetic Therapeutic Market Share by Application in 2021 & 2028
Figure 10. Diagnostic/Clinics Case Studies
Figure 11. ICUs Case Studies
Figure 12. Home Healthcare Case Studies
Figure 13. Diabetic Therapeutic Report Years Considered
Figure 14. Global Diabetic Therapeutic Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 15. Global Diabetic Therapeutic Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Diabetic Therapeutic Market Share by Region: 2021 VS 2028
Figure 17. Global Diabetic Therapeutic Market Share by Players in 2021
Figure 18. Global Top Diabetic Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Therapeutic as of 2021)
Figure 19. The Top 10 and 5 Players Market Share by Diabetic Therapeutic Revenue in 2021
Figure 20. North America Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. North America Diabetic Therapeutic Market Share by Country (2017-2028)
Figure 22. United States Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Diabetic Therapeutic Market Share by Country (2017-2028)
Figure 26. Germany Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Diabetic Therapeutic Market Share by Region (2017-2028)
Figure 34. China Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Diabetic Therapeutic Market Share by Country (2017-2028)
Figure 42. Mexico Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Brazil Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Diabetic Therapeutic Market Share by Country (2017-2028)
Figure 46. Turkey Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Saudi Arabia Diabetic Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Sanofi Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 49. Novo Nordisk Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 50. MSD Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 51. Astrazeneca Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 52. Takeda Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 53. Novartis Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 54. AbbVie Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 55. Eli Lilly Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 56. North China Pharmaceutical Group Corporation Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 57. Huadong Medicine Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 58. Dongbao Pharmaceutical Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 59. Hisun Pharmacy Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 60. KELUN Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 61. Ginwa Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 62. Tianan Pharmaceutical Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 63. Jumpcan Pharmacy Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 64. Guangzhou Baiyun Mountain Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 65. SHIJIAZHUANG YILING PHARMACEUTICAL Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 66. Wanbang Biopharmaceuticals Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 67. Gan & Lee Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 68. Taloph Revenue Growth Rate in Diabetic Therapeutic Business (2017-2022)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock